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Resistance to platinum chemotherapy is one of the main factors driving ovarian cancer mor-
tality, and overcoming platinum resistance is considered one of the greatest challenges
in ovarian cancer research. Genetic and functional evidence points to the homologous
recombination (HR) DNA repair system, and BRCA1 and BRCA2 in particular, as main
determinants of response to platinum therapy. BRCA-mutant ovarian cancers are espe-
cially sensitive to platinum, associated with better survival, and amenable to poly ADP
ribose polymerase inhibitor treatment. Here, we discuss a therapeutic concept that seeks
to disrupt HR capacity via targeting of BRCA1 and BRCA2 functionality in order to reverse
platinum resistance in BRCA-proficient high-grade serous ovarian cancers (HGSOC). We
review the molecular signaling pathways that converge on BRCA1 and BRCA2, their activa-
tion status in ovarian cancer, and therapeutic options to modulate BRCA function. Several
recent publications demonstrate efficient chemosensitization of BRCA-proficient cancers
by combining targeted therapy with standard platinum-based agents. Due to its inherent
genomic heterogeneity, molecularly defined subgroups of HGSOC may require different
approaches. We seek to provide an overview of available agents and their potential use
to reverse platinum resistance by inhibiting the HR system, either directly or indirectly, by
targeting oncogenic activators of HR.
Keywords: high-grade serous ovarian cancer, platinum resistance, BRCA1, BRCA2, cyclin-dependent kinases, cyclin
E1, cyclin-dependent kinase inhibitors, homologous recombination
INTRODUCTION
Platinum-based chemotherapy agents, such as cisplatin, have
been used in the treatment of ovarian carcinoma since the late
1970s. Cisplatin significantly improved the overall survival (OS)
of women with ovarian cancer, leading to its adoption as the back-
bone of most chemotherapeutic regimens (1, 2). Carboplatin, a
cisplatin analog, with an improved toxicity profile and equivalent
therapeutic efficacy has replaced cisplatin as a standard of care
since the mid-1980s (3). The next major advance in chemother-
apy for epithelial ovarian cancer occurred with the introduction of
the mitotic inhibitor paclitaxel, which further improved OS when
combined with platinum (4, 5). Despite these advances, tumor
recurrences still occur in the majority of ovarian cancer patients
and cures remain too infrequent.
Epithelial ovarian cancer is a heterogeneous disease with mul-
tiple histological subtypes and multiple subclones even within
a given patient’s tumor. High-grade serous ovarian cancer
(HGSOC) accounts for the majority of epithelial ovarian cancers
(68%). A recent comprehensive analysis by The Cancer Genome
Atlas (TCGA) revealed HGSOC to be highly genomically unsta-
ble with TP53 gene mutations in more than 96% of cases, and
less frequent mutations in BRCA1 and BRCA2, while mutation
frequencies for all other genes are each <5% (6). Other ovarian
cancer subtypes, such as clear cell and endometrioid ovarian can-
cers have fewer TP53 mutations and are not commonly associated
with BRCA gene mutation (7, 8). In addition, TCGA identified a
plethora of recurrent DNA copy number changes affecting known
oncogenes and tumors suppressor genes. The genomic complex-
ity of HGSOC may explain previous failures of targeted therapy
approaches in unselected patient populations. HGSOC has a poor
prognosis likely due to a combination of factors, including late
stage at presentation and the development of chemoresistance (9).
Most patients with advanced (stage III and IV) HGSOC undergo
cytoreductive surgery followed by combination platinum- and
taxane-based chemotherapy (4, 5). While initial response rates are
quite high (~80%), the majority of patients ultimately relapse due
to the emergence of chemoresistant disease (10). Once patients
develop resistant disease, the options for effective salvage treat-
ment are limited. Clinical trials investigating the inclusion of
alternative chemotherapeutic and biologic agents in recurrent
platinum-resistant ovarian cancer have failed to demonstrate sig-
nificant improvements in OS (11), and the 5-year survival rate
has remained relatively unchanged at 43% for several decades
(12). Thus, there is a critical need to identify and understand the
molecular mechanisms and biological pathways that contribute to
platinum resistance in HGSOC.
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Upon entering a cell, platinum-based compounds generate
inter- and intra-strand DNA adducts that activate the DNA dam-
age response (DDR) and subsequently induce DNA repair (13). In
the absence of a functional DNA repair system, damage accumu-
lates and cell death ensues. Here, we discuss a therapeutic concept
that seeks to reverse platinum resistance in HGSOC via target-
ing the DNA homologous recombination (HR) repair pathway
and the BRCA1 and BRCA2 genes in particular. We will review
the role of BRCA1 and BRCA2 in determining the platinum
response of the cell as well as the concept of synthetic lethal-
ity that has led the introduction of poly ADP ribose polymerase
(PARP) inhibitors for the treatment of BRCA-mutant HGSOC. We
will then outline pharmacological strategies to mimic “BRCAness”
in BRCA-wildtype HGSOC and explore the use of molecularly
targeted agents to exploit this pathway and sensitize the cell to
platinum-induced lethality.
DNA REPAIR PATHWAYS AND PLATINUM RESISTANCE
Platinum resistance is a complex phenotype characterized by
decreased platinum uptake, increased metabolic turnover, inhi-
bition of pro-apoptotic signals, and restored DNA repair capacity
[reviewed in Ref. (14, 15)]. Due to this complexity, the devel-
opment of chemoresistant disease is assumed to be a dynamic
process involving multiple mechanisms. As DNA alkylating agents,
the cytotoxic effects of platinum drugs are largely dependent on
the cell’s ability to detect and repair DNA damage. Several DNA
repair pathways exist and have been linked to platinum resis-
tance. Nucleotide excision repair (NER) is the primary pathway
used for intrastrand platinum adduct removal and is an impor-
tant mediator of responsiveness to platinum-based chemotherapy
(16). High NER activity is correlated with platinum resistance
(17, 18). The mismatch repair (MMR) system functions to repair
single-base pair mismatches and erroneous insertions and dele-
tions that occur during DNA replication and recombination.
Mutation and decreased expression of MMR components, MLH1
and MSH2, have been documented in ovarian and other cancers,
and correlated with prognostic indicators including chemotherapy
response (19, 20). In ovarian cancer, deficiencies in MMR and sub-
sequent microsatellite instability (MSI) are estimated to account
for tumor development in <10% of cases (20). However, the role
of MMR inactivation and MSI in platinum response in HGSOC
remains controversial, as several studies have reached conflicting
conclusions (21, 22).
The most lethal lesions induced by platinum agents are DNA
double strand breaks (DSBs), which are a result of platinum-
induced interstrand crosslinks. These DSBs are particularly toxic
as both strands of DNA are affected and there is no intact com-
plimentary strand to utilize as a template for repair. DSBs are
repaired by two major pathways within the cell: non-homologous
end-joining (NHEJ) and HR. The preferred method of DSB repair
is HR, as NHEJ is inherently mutagenic and can result in undesir-
able insertions and/or deletions. HR is a highly conserved pathway
that provides error-free repair of DSBs by using the intact sister
chromatid as a template, which fixes the break while maintaining
sequence integrity. Due to this requirement, HR occurs during G2
and S phases of the cell cycle (23). Two of the most well-known HR
proteins are BRCA1 and BRCA2. BRCA1 is a multipurpose protein
that participates in DDR activation, cell cycle checkpoint initia-
tion, and DSB repair as a component of several supercomplexes
(24). In HR, BRCA1 is localized to DSBs through its association
with the abraxas-RAP80 complex, and promotes 5′-end resection
of the break in cooperation with other proteins (25, 26). BRCA1 is
also required in the later stages of HR, where its interaction with
PALB2 and BRCA2 is necessary for the recruitment of RAD51 to
DSBs and subsequent strand invasion of the sister chromatid for
DNA repair (27, 28). Of note, the only well-documented function
of BRCA2 is its direct binding of RAD51 in HR (29).
THE BRCA PARADOX
Mutations inBRCA1 orBRCA2 are found in the majority of hered-
itary breast and ovarian cancers and greatly increase lifetime risk
for both cancers. Moreover, somatic mutations in at least one of
the BRCA genes are present in a significant proportion of spo-
radic HGSOC, rendering BRCA1 and BRCA2 as two of the most
frequently mutated tumor suppressor genes that guard against the
transformation of serous epithelium to HGSOC. However, once
an advanced tumor has developed, BRCA-mutant HGSOC are
associated with better survival than wildtype HGSOC. This seem-
ing paradox was first described by comparing outcomes of women
with hereditary epithelial ovarian cancer to those of women with
sporadic ovarian cancer. BRCA mutation carriers had significantly
prolonged survival compared to patients with sporadic disease
(30, 31). A meta-analysis of 26 studies comparing 1213 cases with
germline BRCA mutations and 2666 non-carriers determined that
the 5-year survival rate was 36% for non-carriers, 44% for BRCA1
mutation carriers, and 52% for BRCA2 mutation carriers (32).
Further, the analysis by TCGA of 316 HGSOC confirmed that
BRCA-mutant HGSOC (both hereditary and sporadic) are associ-
ated with better survival thanBRCA-wildtype HGSOC (6). Collec-
tively, these studies suggest that BRCA-deficient HGSOC respond
better to standard therapies, specifically platinum chemotherapy,
compared to BRCA-wildtype cancers, and further, that an intact
HR system seems to be crucial for the survival of platinum-treated
ovarian cancer cells.
RESTORED BRCA FUNCTION IN PLATINUM-RESISTANT CANCERS
An independent line of evidence supporting intact BRCA and
HR function as one of the main determinants of chemosensi-
tivity emerged from the analysis of platinum-resistant cells in
which BRCA function had been restored by secondary mutations.
Sakai et al. analyzed cisplatin-resistant subclones of the CAPAN1
pancreatic cancer cell line, which carries a 6174delT frame-shift
mutation and lacks wildtype BRCA2 (33). Fifty percent (7/14) of
the resistant clones had restored expression of BRCA2 by intra-
genic deletions, insertions, or deletions/insertions. In all clones,
the reading frame had been restored, and a functional protein was
expressed. Similarly, frame-shift mutations in the BRCA1 gene can
be reversed by secondary mutations in cisplatin-resistant ovarian
cancers (34, 35). Mechanistically, secondary mutations could be
the result of error-prone DNA repair in cells that lack a functional
HR system. In the presence of cisplatin, cancer cells with restored
HR function are expected to have a strong selection advantage and
may thus become the dominant cell clone in recurrent cancers. In
a mouse model of mammary tumorigenesis induced by combined
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loss of Brca1 and p53 (K14-Cre; Brca1flox/flox; p53flox/flox), Brca1-
null tumors do not become cisplatin-resistant over the course of
at least six cycles of cisplatin treatment (36). In contrast to point
mutations or small insertions/deletions found in human cancers,
large genetic deletions resulting from Cre-mediated recombina-
tion in this mouse model are irreversible. The inability of these
murine cancer cells to restore functional Brca1 expression may
explain their sustained platinum sensitivity. Interestingly, plat-
inum treatment cannot fully eradicate the breast tumors in this
model, leaving a small fraction of surviving cells that can repop-
ulate the tumor following withdrawal of cisplatin (36). It is
tempting to speculate that the few surviving clones escape from
platinum-induced death by employing mechanisms related to
reduced proliferation, such as acquisition of cancer stem cell prop-
erties, or complete exit from the cell cycle [dormancy, reviewed in
Ref. (37)].
EXPLOITING LOSS OF BRCA FUNCTION IN A SYNTHETIC LETHAL
APPROACH USING PARP INHIBITORS
Synthetic lethality is defined as death resulting from concomi-
tant mutation of two genes if mutation of either gene alone
is associated with viability but mutation of both is lethal (38).
This concept can be expanded to more than two genes and to
pharmacologically modulated gene activity, e.g., loss-of-function
following pharmacological inhibition of protein that is critically
required in cancer cells. In the context of anticancer therapy, a
synthetic lethal approach may take advantage of somatic muta-
tions that render the tumor sensitive to specific chemotherapeutic
agents but spare normal cells without the mutation. Alterna-
tively, tumor-specific dependency on individual genes or signal-
ing pathways (“oncogene addiction”) can expose synthetic lethal
vulnerabilities.
In ovarian cancer, the most prominent example of synthetic
lethality involves PARP inhibition inBRCA-mutant cancers. PARP
is a DNA repair enzyme and part of the base excision repair (BER)
pathway. The HR defect in BRCA-mutant cancers renders them
particularly sensitive to inhibition of other DNA repair pathways
that compensate for loss of HR activity. Concomitant defects in
the HR and BER pathways are synthetic lethal; DNA damage accu-
mulates in PARP inhibitor-treated BRCA-mutant cells and may be
repaired by error-prone mechanisms, such as NHEJ. As a result,
complex chromatid rearrangements ensue that lead to G2/M phase
cell cycle arrest and subsequent cell death (39).
Based on the concept of synthetic lethality, several PARP
inhibitors (PARPi), such as Olaparib, have entered clinical trials
for ovarian cancer and other BRCA-associated cancers. Ovar-
ian cancer-specific trials in patients with recurrent BRCA-mutant
cancers showed high response rates between 30 and 60% for Ola-
parib (40, 41) and increased progression-free survival (42). While
BRCA-mutant cancers are especially sensitive to PARPi, a sig-
nificant proportion of BRCA-proficient HGSOC are thought to
exhibit a “BRCAness” phenotype, which is caused by HR defects
other than BRCA mutation (43). HGSOC with the BRCAness
phenotype are also predicted to be sensitive to PARPi, and
the identification of these cancers within the pool of BRCA-
wildtype HGSOC could increase the proportion of PARPi-eligible
patients.
TARGETING HR FUNCTION AS A CHEMOSENSITIZATION
STRATEGY
In addition to identifying cancers with inherent HR defects, the
active modulation of HR capacity in BRCA-proficient cancers via
targeting of BRCA function is an attractive therapeutic concept.
Quinn et al. showed that downregulation of BRCA1 by RNAi
increased sensitivity to cisplatin in ovarian cancer cell lines (44),
thus providing a rationale for the use of pharmacological agents in
order to inhibit BRCA function. Several recent publications sug-
gest that pharmacological targeting of BRCA1 and BRCA2 can
sensitize BRCA-wildtype cancers to platinum-based chemother-
apy and PARP inhibition. In the following sections, we will outline
potential therapeutic strategies that target BRCA loss-of-function
as a result of transcriptional downregulation or inhibition of pro-
tein activity. We will describe the molecular pathways regulating
BRCA gene expression and their activation in HGSOC, and the
transcription factors that mediate transcriptional activation of
BRCA1 and BRCA2. Finally, we will discuss different classes of
targeted compounds for their potential use as chemosensitizing
agents in BRCA-proficient HGSOC. We hypothesize that molec-
ular targeting of HR function can reverse platinum resistance in
HGSOC.
REGULATION OF BRCA1 AND BRCA2
Control of BRCA1 and BRCA2 activity involves transcriptional
regulation and post-translational modifications of the BRCA pro-
teins. As part of the DDR, BRCA1 is phosphorylated by CHEK2
and ATM in normal cells and cancer cells following irradiation
or exposure to alkylating agents [reviewed in Ref. (24)]. While
DDR inhibitors may be able to sensitize cells to DNA-damaging
agents, this article focuses on targeting genes and pathways that are
activated specifically in cancer cells and required for BRCA gene
expression and/or activity. Importantly, many oncogenic drivers
and their downstream mediators, such as proliferation-associated
transcription factors, are positive regulators of BRCA1 andBRCA2.
Activation of BRCA1 and BRCA2 by oncogenes offers the oppor-
tunity to selectively sensitize cancer cells to platinum by targeting
defined genetic alterations that are not present in normal cells.
Inhibition of oncogenic drivers may result in downregulation of
BRCA mRNA and/or inactivation of BRCA proteins.
BRCA1 and BRCA2 are regulated in a cell cycle-dependent
manner. In cultured cells, BRCA1 and BRCA2 mRNA expression
is low under conditions of serum starvation, confluency, or other
factors that induce G0 cell cycle arrest (45, 46). In contrast, rapidly
proliferating cells express high levels of both BRCA1 and BRCA2
mRNA. This is in line with the documented function of BRCA1
and BRCA2 in HR, which occurs during the S and G2 phases of
the cell cycle, and ensures DNA replication fidelity.
Transcriptional regulation of BRCA1 and BRCA2 by ETS, MYC, and
E2F
Several classes of transcription factors are involved in cell cycle
progression and have been shown to regulate BRCA1 and BRCA2
expression. Initial analysis of the human BRCA1 promoter iden-
tified a core promoter region that extends from about 250 bp
upstream of the transcription start site (TSS) into the first exon (47,
48). This <300 bp region, which was associated with the highest
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FIGURE 1 | ETS, MYC, and E2F regulate the BRCA1 and BRCA2
promoters. (A)The regulation of the BRCA1 promoter is complex and
several regulatory sites have been identified. The positive regulatory region
(PPR) located at the 5′ end of the promoter has been shown to be necessary
and sufficient for BRCA1 transcription, and contains sites such as the
cyclic-AMP response element (CRE). Within the PPR, the three consecutive
ETS factor binding sites are known as the RIBS element and have been
shown to be bound by GA-binding protein α/β (GABPα/β), an ETS factor
family member. (B)The BRCA2 promoter contains several conserved
recognition motifs for transcription factors including E-box, E2F, and ETS
(49). BRCA2 gene transcription may be activated by the binding of ELF1, an
ETS factor, to the ETS recognition motifs or by the binding of USF1 and
USF2, basic helix-loop-helix leucine zipper family members, to the E-box.
Additionally, NF-κB can also bind the BRCA2 promoter and induce genes
expression (59). Functionally characterized binding sites are depicted by solid
colored boxes. Putative binding sites are depicted by patterned boxes and
were identified using the MatInspector software (Genomatix, Munich).
Diagrams are not drawn to scale.
promoter activity in reporter assays, contains several E2F and ETS
binding sites as well as a CREB binding site (Figure 1A). The
human BRCA2 promoter has been characterized to a lesser extent
but also contains functionally relevant E2F and ETS binding sites
within its proximal region (Figure 1B) (49). Traditionally, E2F
transcription factors are considered as the main mediators of G1–
S progression. Activator E2Fs (E2F1–3) transcribe many of the
genes involved in DNA replication, checkpoint control, and DNA
repair (50). Importantly, E2F function couples proliferation and
DNA repair by coordinating the induction of genes required for
DNA synthesis, such as thymidine kinase (TK1) and dihydrofo-
latereductase (DHFR), and DNA repair, such as BRCA1, BRCA2,
and RAD51 (51). However, mouse models have demonstrated that
while activator E2Fs are critical for cell cycle progression in some
cell systems, E2F-independent proliferation occurs in others (52–
54). There is mounting evidence that other classes of transcription
factors can compensate for loss of E2F function in some cell types.
For example, E2f1–3-null mouse retinal progenitor cells contin-
ued to divide possibly due to compensation by Mycn, a member
of the MYC family of basic helix-loop-helix transcription factors
(52). In breast cancer cells, MYC was found to directly regulate
the BRCA1 promoter via binding to distal regulatory regions (55)
(Figure 1A). In addition, oncogenic ETS family transcription fac-
tors were shown to induce a subset of E2F target genes (56, 57),
including BRCA2 (58). Thus, a number of cancer-relevant tran-
scription factors regulate BRCA1 and BRCA2. In order to achieve
effective downregulation of BRCA transcription, it is necessary to
identify and target the main drivers of BRCA gene expression in
different subgroups of HGSOC.
Pharmacologic targeting of oncogenic transcription factors driving
BRCA expression
Some of the transcription factors driving BRCA gene expression
are known oncogenes (MYC) or putative oncogenes in ovarian
cancer, based on functional data and evidence of genetic activation
in primary HGSOC:MYC is amplified in 30% of HGSOC (6), and
E2F3 is amplified in about 10% (60). While most transcription
factors are not easily druggable with currently available agents,
targeting of BET bromodomain proteins has been described as
an effective means of inhibiting MYC-dependent transcription
(61). Preclinical studies with the small molecule inhibitor JQ1 have
yielded promising results in MYC-dependent hematologic malig-
nancies, medulloblastoma (62), and KRAS-mutant lung cancer
(63), but its compatibility with platinum-based chemotherapy,
as well as its effect on BRCA gene expression, has yet to be
established.
ETS family transcription factors have been implicated in plat-
inum resistance. ETS1 was shown to be overexpressed in C13 cells,
a cisplatin-resistant derivate of 2008 ovarian cancer cells (64),
and ectopic expression of ETS1 in 2008 cells conferred platinum
resistance. Similarly, ETV4 (PEA3) is overexpressed in cisplatin-
resistant PEO1 ovarian cancer cells (65). Both the BRCA1 and
the BRCA2 promoter are bound and activated by ETS transcrip-
tion factors: GA-binding protein α/β (GABPα/β) binds the RIBS
element in the BRCA1 core promoter (Figure 1A), and overex-
pression of GABPα/β in breast cancer cells was able to stimulate
BRCA1 promoter activation (66). Similarly, BRCA2 gene tran-
scription may be activated by the binding of ELF1, another ETS
family member (49) (Figure 1B).
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FIGURE 2 |Targeting cyclin E1-dependent ovarian cancers. (A) Cyclin
E1 function is dependent on it interaction with CDK1 and CKD2. CDK1/2
inhibitors inhibit this interaction and cause E2F-mediated transcriptional
downregulation of BRCA1 and BRCA2. CDK1/2 inhibition may also
prevent their phosphorylation and subsequent activation of the BRCA1
and BRCA2 proteins. Alternatively, use of Bortezomib, a proteasomal
inhibitor, can inhibit HR function and potentially sensitize cyclin
E1-dependent tumors to platinum-based chemotherapy. NLS, nuclear
localization signal; BRCT, BRCA1 C-terminus domain. (B) Kaplan–Meier
curve showing that CCNE1 overexpression (n=32 tumors, Z -score≥2) in
HGSOC was associated with significantly reduced overall survival (OS) as
compared with tumors with normal or low expression of CCNE1 (n=97
tumors, Z -score<2). Median OS for cancers with CCNE1 high and
normal/low expression were 33.44 and 47.47 months, respectively. A
subset of 129 HGSOC tumors from the TCGA dataset was used for this
analysis and was selected based on p53-mutant and BRCA1- and
BRCA2-wildtype status as well as availability of RNAseq V2 data. Data
were accessed using the cBioPortal for Cancer Genomics maintained by
the Computational Biology Center at Memorial Sloan-Kettering Cancer
Center. (C) Increased expression of HR and DNA repair-related genes in
cyclin E1-overexpressing tumors. Known E2F targets, E2F1, BIRC5
(survivin), CDK1 (CDC2), andTK1 are included for reference. Median
Z -score values for each CCNE1 expression subset are shown; P values
were determined using Student’s t -test.
Studies in prostate cancer suggest a targeting strategy for onco-
genic ETS factors. Constitutive activation of ERG, ETV4, or ETV5
following gene fusion with the TMPRSS2 promoter renders the
fusion gene oncogenic in prostate cancer cells (67). ERG was shown
to interact with PARP and require PARP activity for its transcrip-
tional activity. Inhibition of PARP by Olaparib specifically sensi-
tized ERG-driven prostate cancer xenograft to the alkylating agent,
temozolomide (68). Similarly, ETS-dependent, BRCA-proficient
ovarian cancers may be susceptible to PARPi. However, ETS gene
fusions have not been detected in ovarian cancer, and biomarkers
of ETS dependency have yet to be identified in HGSOC. Thus,
direct targeting of transcription factors is an interesting therapeu-
tic strategy, but requires additional studies prior to translation into
the clinic.
REGULATION OF BRCA1 AND BRCA2 BY ONCOGENIC SIGNALING
A more immediate option may present itself in targeting the
signaling pathways that lead to activation of transcription
factors. ETS, MYC, and E2F transcription factors are downstream
mediators of several oncogenic signaling pathways (Figures 2A
and 3). Inhibition of these pathways may result in loss of tran-
scriptional activity and subsequent downregulation of BRCA
gene expression. TCGA identified the retinoblastoma (RB)
pathway, phosphatidylinositide 3-kinase (PI3K), and RAS sig-
naling as the most frequently altered signaling pathways in
HGSOC (6).
The RB pathway
The RB pathway governs G1/S transition in mammalian cells. In
proliferating cells, growth factor or oncogene-induced expression
of cyclin D results in activation of the cyclin-dependent kinases,
CDK4/6, and inactivation of the RB protein. RB forms complexes
with E2F1–3 proteins and inhibits their transactivating activity.
Phosphorylation of RB by CDK/cyclin complexes unleashes E2F
activity, resulting in expression of E2F target genes, including
cyclin E1 (CCNE1), CDK2, and E2F1–3, which amplify the signal
in a positive feedback loop and transition the cell from G1 to S
phase. The CDK/cyclin–RB–E2F axis (RB pathway) is frequently
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FIGURE 3 |Targeting the RTK–PI3K/MAPK axis. RTKs, including
ERBB2/ERBB3 and IGF-1R, are activated by their respective growth signals
and are capable of signaling through both the PI3K–AKT and MAPK pathways.
Subsequent activation of AKT and ERK allows for the phosphorylation of
multiple transcription factors including ETS and MYC that are important in
BRCA1 and BRCA2 gene transcription. Activation of ERK also induces cyclin
D1 production, which in complex with CDK4/6 promotes E2F-mediated gene
transcription. We propose that BRCA1 and BRCA2 expression could be
inhibited at each of these levels; inhibitors of RTKs, PI3K signaling, MAPK
signaling, and CDK4/6 are listed. PARPi, such as Olaparib, may also
downregulate BRCA gene expression as PARP1 is required as a co-factor for
some ETS family members.
deregulated in cancer as a result of mutations or deletions in
RB1 (10% in HGSOC), amplification of cyclin genes (CCNE1 is
amplified in 20% of HGSOC, CCND1 is amplified in 4%), or
functional loss of endogenous CDK inhibitors (CDKi), such as
p16INK4A (CDKN2A, downregulated in 30% of HGSOC) (6). The
net result of RB pathway alterations in cancer is increased pro-
liferation and elevated E2F activity compared to normal tissue.
Wang et al. studied regulation of the murine Brca1 promoter by
the CDK/cyclin–RB–E2F axis. Using a luciferase Brca1 promoter
construct (+6 to −1003), ectopic cyclin D1 induced luciferase
activity while RB suppressed activity. They also identified a con-
served 5′-GCGGGAAT -3′ E2F binding site at −37 to −19 rel-
ative to the TSS (−23 to −5 in the human BRCA1 promoter)
and demonstrated physical binding of E2F protein to this region
(69) within the BRCA1 core promoter (Figure 1A). Hence, the
RB pathway directly controls BRCA expression via regulation of
E2F activity, and targeting of cancer-specific RB pathway lesions,
such as CCNE1, may result in downregulation of BRCA gene
expression.
TARGETING CCNE1 DEPENDENCY
Direct targeting of CDK/cyclin signaling
CCNE1-amplified cancers make up a large subgroup (20%) of
HGSOC that lack BRCA mutations (6) and are therefore less
likely to respond to PARPi. For likely the same reason, CCNE1-
amplified tumors were reported to be among the most chemore-
sistant HGSOC (70), and recurrent CCNE1-amplified HGSOC
continue to be dependent on the presence of the CCNE1 ampli-
con (71). The CCNE1 gene product, cyclin E1, is a co-factor
for cyclin-dependent kinases 1 and 2 (CDK1/2) and activates
BRCA1 and BRCA2 transcription via E2F transcription factors
(50) (Figure 2A). Therefore, CCNE1-amplified HGSOC often
express high levels of wildtype BRCA1 and exhibit an “anti-
BRCAness” phenotype in terms of their relative resistance to
platinum chemotherapy. Using the TCGA dataset, we show that
cyclin E1-overexpressing, BRCA-wildtype HGSOC have signif-
icantly reduced OS compared to BRCA-wildtype cancers with
lower cyclin E1 expression (Figure 2B). This suggests that high
levels of cyclin E1 confer an added advantage to BRCA-proficient
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cancers. We attribute this, at least in part, to increased expression of
several HR genes, including BRCA1, BRCA2, RAD51, all of which
have significantly higher RNA levels in cyclin E1-overexpressing
cells (Figure 2C).
CDK inhibitors may be a therapeutic option for cyclin E1-
dependent HGSOC, including CCNE1-amplified cancers. Cyclin
E1 has the highest affinity for CDK2, its main binding partner in
actively cycling cells (72–74), and CDK1 (CDC2) (75). Both CDK2
and CDK1 directly phosphorylate BRCA1 (76, 77) (Figure 2A).
Furthermore, a functional link between CDK1 and BRCA1 has
been established in lung cancer. Using an inducible shRNA target-
ing CDK1 in a human non-small cell lung cancer cell line, Johnson
et al. showed that CDK1 contributes to S phase checkpoint con-
trol following DNA damage (77). CDK1 directly phosphorylated
BRCA1 at several serine residues and is required for the forma-
tion of BRCA1 foci following DNA damage. Genetic depletion or
pharmacological inhibition of CDK1 sensitized BRCA1-proficient
cancer cell lines to cisplatin (77) and PARPi (78). Similarly, BRCA2
is phosphorylated by both CDK1 and CDK2 (79).
While there are still no selective inhibitors of CDK1 or CDK2,
latest generation CDKi have increased specificity and potency
compared to early CDKi, such as flavopiridol, which failed in
the clinic. The compound Dinaciclib inhibits CDK1/2/5/9 at
low nanomolar concentrations (IC50 values: CDK1: 3 nM, CDK2,
1 nM, CDK5: 1 nM, CDK9: 4 nM). It induces apoptosis in model
systems and prevents tumor progression in A2780 ovarian cancer
xenografts (80, 81). We hypothesize that of the currently avail-
able CDKi, Dinaciclib may have the best therapeutic potential in
cyclin E1-dependent ovarian cancer. Our unpublished data show
that Dinaciclib exposure results in downregulation of BRCA1 and
BRCA2 and sensitized cyclin E1-dependent ovarian cancer cells to
cisplatin. Hence, Dinaciclib may have a dual effect on BRCA1 and
BRCA2 by causing E2F-mediated transcriptional downregulation
and inhibiting CDK1/2-mediated activation of the BRCA proteins
(Figure 2A).
Dinaciclib is currently being evaluated in a phase 3 clinical trial
for chronic lymphocytic leukemia (CLL) and may have clinical
potential in cyclin E1-dependent HGSOC as a chemosensitizing
agent. In order to select eligible patients, CCNE1-amplified can-
cers can be easily identified by fluorescence in situ hybridization
(FISH). Other available CDK2 inhibitors, including Roscovitine,
SNS032 (82), and AZD5438 (83), may have similar chemosensi-
tizing potential. CDK1, the only mammalian CDK required for
proliferation in all cell types (84), is not inhibited by SNS032, ren-
dering this compound potentially less potent but also less toxic
to normal cells. In principle, other CDKi such as the CDK4/6
inhibitor Palbociclib (formerly PD0332991) could be used to
reduce BRCA expression in cyclin D-dependent HGSOC. How-
ever, Palbociclib was shown to be cytostatic in most systems
(85–87) and may thus interfere with the cytotoxic activity of
platinum agents.
Targeting of HR components induces synthetic lethality in
CCNE1-amplified HGSOC
An independent approach to target CCNE1-amplified HGSOC
identified the proteasome inhibitor, Bortezomib (88). In contrast
to CDKi, Bortezomib primarily affects the homologous repair
system itself, resulting in synthetic lethality in CCNE1-amplified
cancer cells: a genome-wide shRNA screen in 102 cancer cell lines
revealed that BRCA1 was specifically required inCCNE1-amplified
cell lines. Genetic depletion of BRCA1 resulted in significant loss
of viability inCCNE1-amplified cells, including the ovarian cancer
cell line OVCAR3, whereas a lesser effect was observed in CCNE1-
wildtype cells, such as the SKOV3 cell line (88). This suggests a
synthetic lethal relationship between CCNE1 amplification and
loss of BRCA1 function and provides a potential explanation for
the observed mutual exclusivity between CCNE1 amplification
and BRCA mutation (6, 89). In addition to BRCA1, the shRNA
screen identified the DNA repair genesATR andXRCC2 as specific
genetic hits in CCNE1-amplified cell lines, suggesting that inhibi-
tion of the DDR may be a therapeutic strategy inCCNE1-amplified
ovarian cancer. To this end, the authors tested Bortezomib, a
potent inhibitor of the HR system, in a panel of ovarian cancer
cell lines and found that CCNE1-amplified lines were most sensi-
tive. While Bortezomib had minimal activity as a single agent in
recurrent ovarian cancer (90) combination with platinum resulted
in clinical activity (91). As discussed for CDKi, specific selection of
patients with CCNE1-amplified cancers for Bortezomib treatment
may further increase the response rate.
RECEPTOR TYROSINE KINASE, PI3K, AND RAS SIGNALING
In addition to genetic aberrations within the RB pathway, several
oncogenic signals contribute to cell cycle deregulation and E2F
activity. Oncogenic KRAS (amplified in 11% of HGSOC), MYC,
and receptor tyrosine kinases (RTK) all converge on cyclin D and
require its function for their oncogenic activity (92–94). Moreover,
a synthetic lethal relationship was described for KRAS and CDK4,
the binding partner of cyclin D (94). KRAS and ERBB2 signal
through the mitogen-activated kinase (MAPK) signaling pathway,
which culminates in activation of ERK (Figure 3). Phosphoryla-
tion by ERK activates multiple cellular target proteins, including
ETS, CREB, and MYC. The molecular link between oncogenic
signaling pathways and expression of BRCA1 and BRCA2 offers
additional opportunities for therapeutic intervention, including
direct targeting of ERBB2 and other RTK, targeting of the MAPK
pathway by specific MEK or ERK inhibitors, or targeting of the
PI3K–AKT axis by specific inhibitors (Figure 3). However, due to
the complex signaling events elicited by RTK and other oncogenic
pathways, regulation of BRCA gene expression is only one of many
downstream events, some of which may actually interfere with the
intended chemosensitizing effect. Functional studies are needed
to determine the compatibility of individual targeted agents with
platinum and PARPi.
Targeting RTK signaling and downstream pathways
Although amplifications or mutations of individual RTK are
rare events in primary HGSOC (ERBB2 amplification: 3%,
ERBB3 amplification:<5%, IGF1R amplification:<4%, Figure 3),
altered ERBB receptor signaling and overexpression of the down-
stream RTK mediator ETV4 were found in cisplatin-resistant
PEO1 cells (65). RTK can be targeted directly by small mole-
cule inhibitors (e.g., Lapatinib for ERBB2) or antagonistic anti-
bodies (e.g., Trastuzumab or Pertuzumab for ERBB2). How-
ever in unselected patients, the addition of Pertuzumab to
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carboplatin-based chemotherapy did not result in prolonged
progression-free survival (95), highlighting the importance of
patient selection and companion diagnostics to identify likely
responders to RTK inhibitors. Activation of the MAPK and PI3K–
AKT signaling pathways by RTK, or as a result of amplification,
offers additional potential therapeutic targets [also reviewed in
Ref. (96)]. Both PIK3CA, the gene encoding the catalytic subunit
of PI3K, and the AKT genes are frequently amplified in HGSOC
(PIK3CA: 28%, AKT1: 5%, AKT2: 8%, AKT3: 9%), indicating
their oncogenic roles in ovarian cancer. Interestingly, AKT was
shown to directly phosphorylate BRCA1 at serine 694 and pro-
mote its protein stability (97). A second AKT phosphorylation site
at threonine 509 was described but its functional implications are
unknown (98).
Functionally, a recent study in triple negative breast cancer
demonstrated that PI3K signaling was required for BRCA1 func-
tion. Ibrahim et al. showed that inhibition of PI3K phenocopied
loss of BRCA1 and induced synthetic lethality in combination
with Olaparib (99). Loss of PI3K resulted in reduced BRCA1
expression both in cell line models and in patient-derived tumor
xenografts. Combined treatment with BKM120, a small molecule
PI3K inhibitor, and Olaparib significantly delayed tumor progres-
sion in two out of three xenografts whereas single agent treatment
had little effect on tumor progression. On the molecular level,
the MAPK pathway mediated the transcriptional effect on BRCA1
via ETS1-dependent downregulation of BRCA1 (99). Interestingly,
BKM120 treatment resulted in activation of the MAPK path-
way and phosphorylation of ETS1 by ERK, indicating a repressor
function for ETS1 in this system. This finding highlights the com-
plexity of BRCA gene regulation and its dependency on genetic
context. Due to feedback mechanisms and functional compensa-
tion among RTKs, downstream kinases, and transcription factors,
specific pharmacological combinations may be limited in their
effectiveness to small genetically defined subsets of HGSOC. More-
over, as a result of the genetic complexity and genomic instability
that is a hallmark of HGSOC, individual cancers are likely to har-
bor or develop resistant cell clones to any given combination. Thus,
it will be important to identify multiple agents targeting different
pathways, all of which should be characterized with respect to:
(1) their ability to induce BRCA loss-of-function, (2) their com-
patibility with platinum and/or PARPi, both in terms of toxicity
and mechanism of action, and (3) accompanying biomarkers that
allow for careful patient selection.
TARGETING BRCA PROTEIN STABILITY
A different approach to inhibit BRCA1 function involves targeting
of the chaperone protein heat shock protein 90 (HSP90), required
for BRCA1 protein stability (100). Interestingly,HSP90AB1 is also
amplified in a small subset of HGSOC (6). Specific inhibition of
HSP90 in BRCA1-proficient breast cancer cells-induced BRCA1
ubiquitination and proteasomal degradation ultimately resulting
in compromised DSB repair by HR. HSP90 inhibition sensitized
BRCA1-proficient breast and ovarian cancer cells in vitro to car-
boplatin treatment at concentrations similar to BRCA1-mutant
cells (100). In a subsequent study, treatment with the pan-histone
deacetylase complex (HDAC) inhibitors vorinostat or panobi-
nostat induced hyperacetylation of HSP90 gene (HSP90AA1I0),
thereby inhibiting its chaperone function and leading to protea-
somal degradation and depletion of BRCA1 (101). Of clinical
significance, treatment of human triple negative breast cancer cell
lines with vorinostat was able to induce BRCA1 degradation and
a subsequent BRCAness phenotype, which synergistically induced
cell death in combination with PARPi or cisplatin (102). Based
on these preliminary studies, it is suggested that treatment of
platinum-resistant HGSOC with HDAC inhibitors may also be
able to induce a BRCAness phenotype and resensitize these cells
to platinum or other targeted agents. Trials evaluating vorinos-
tat as a single agent in recurrent epithelial ovarian cancer showed
it had limited activity (103). Vorinostat may show better ther-
apeutic efficacy as a biologic response modifier in combination
with platinum-based chemotherapy and trials assessing this use in
ovarian cancer are underway.
CONCLUDING REMARKS
In HGSOC cells, a functional HR system and intact BRCA1 and
BRCA2 function are often associated with resistance to platinum-
based chemotherapeutic agents and PARPi. A plethora of targeted
agents are currently available to modulate BRCA function via tran-
scriptional or post-translational intervention. With the advent of
novel diagnostic tools, such as the use of deep sequencing to repeat-
edly profile cancers throughout their evolution, it should become
possible to predict rational therapeutic combinations that pre-
vent or at least delay the onset of platinum resistance and should
ultimately result in improvements in OS.
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